Literature DB >> 1316870

Post-transplant lymphoproliferative disorders: a morphologic, phenotypic and genotypic spectrum of disease.

S H Swerdlow1.   

Abstract

The post-transplant lymphoproliferative disorders represent a spectrum of life-threatening, generally Epstein-Barr virus-associated lymphoid proliferations which occur in the setting of exogenous immunosuppression following organ transplantation. Histopathological, phenotypic, genotypic and Epstein-Barr virus studies have revealed a broad range of abnormalities. At one end of the spectrum, they are polymorphic polyclonal proliferations with many features of a florid viral infection and, at the other end, they are monomorphic and monoclonal which would fulfill the criteria for a conventional non-Hodgkin's lymphoma, usually of B-cell type. Some patients have both polyclonal and monoclonal lesions and some have two or more monoclonal populations. Finally, because of the varied appearances, different classification schemes have been developed with reported prognostic implications.

Entities:  

Mesh:

Year:  1992        PMID: 1316870     DOI: 10.1111/j.1365-2559.1992.tb01007.x

Source DB:  PubMed          Journal:  Histopathology        ISSN: 0309-0167            Impact factor:   5.087


  14 in total

1.  High levels of Epstein-Barr virus DNA in blood of solid-organ transplant recipients and their value in predicting posttransplant lymphoproliferative disorders.

Authors:  F Baldanti; P Grossi; M Furione; L Simoncini; A Sarasini; P Comoli; R Maccario; R Fiocchi; G Gerna
Journal:  J Clin Microbiol       Date:  2000-02       Impact factor: 5.948

2.  Post-transplant plasmacytoma without Epstein-Barr virus infection occurring rapidly after unrelated allogeneic bone marrow transplantation.

Authors:  Keiki Kawakami; Setuko Miyanishi; Yasuyuki Nakano; Hidetsugu Mitani; Makoto Nakao; Tetsuya Murata; Yohichiro Baba; Shigeo Nakamura
Journal:  Int J Hematol       Date:  2008-11-27       Impact factor: 2.490

3.  Expanding the Spectrum of EBV-positive Marginal Zone Lymphomas: A Lesion Associated With Diverse Immunodeficiency Settings.

Authors:  Shunyou Gong; Genevieve M Crane; Chad M McCall; Wenbin Xiao; Karthik A Ganapathi; Nathan Cuka; Theresa Davies-Hill; Liqiang Xi; Mark Raffeld; Stefania Pittaluga; Amy S Duffield; Elaine S Jaffe
Journal:  Am J Surg Pathol       Date:  2018-10       Impact factor: 6.394

4.  A retrocardiac shadow in an immunocompromised patient.

Authors:  F U Huwez; M J Stewart; A R McPhaden; I S Stewart; S K Naik; D Richens; D J Wheatley
Journal:  Postgrad Med J       Date:  1997-06       Impact factor: 2.401

5.  The Impact of EBV Status on Characteristics and Outcomes of Posttransplantation Lymphoproliferative Disorder.

Authors:  M R Luskin; D S Heil; K S Tan; S Choi; E A Stadtmauer; S J Schuster; D L Porter; R H Vonderheide; A Bagg; D F Heitjan; D E Tsai; R Reshef
Journal:  Am J Transplant       Date:  2015-05-18       Impact factor: 8.086

6.  Use of quantitative competitive PCR to measure Epstein-Barr virus genome load in the peripheral blood of pediatric transplant patients with lymphoproliferative disorders.

Authors:  D T Rowe; L Qu; J Reyes; N Jabbour; E Yunis; P Putnam; S Todo; M Green
Journal:  J Clin Microbiol       Date:  1997-06       Impact factor: 5.948

7.  Detection of Epstein-Barr virus DNA in sera from transplant recipients with lymphoproliferative disorders.

Authors:  A P Limaye; M L Huang; E E Atienza; J M Ferrenberg; L Corey
Journal:  J Clin Microbiol       Date:  1999-04       Impact factor: 5.948

Review 8.  Epstein-Barr virus, infectious mononucleosis, and posttransplant lymphoproliferative disorders.

Authors:  M A Nalesnik; T E Starzl
Journal:  Transplant Sci       Date:  1994-09

9.  Post-transplant lymphoproliferative disorders.

Authors:  K J Lewin
Journal:  Pathol Oncol Res       Date:  1997-09       Impact factor: 3.201

10.  Quantitative analysis of Epstein-Barr virus load by using a real-time PCR assay.

Authors:  H Kimura; M Morita; Y Yabuta; K Kuzushima; K Kato; S Kojima; T Matsuyama; T Morishima
Journal:  J Clin Microbiol       Date:  1999-01       Impact factor: 5.948

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.